Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-beta-D-ribofuranosylselenazole-4-carboxamide.
The new synthetic nucleoside analogue, 2-beta-D-ribofuranosylselenazole-4-carboxamide, was evaluated for its effects upon the growth and maturation of the human promyelocytic leukemia cell line, HL-60. At a concentration of greater than or equal to 1 nm, this agent was found both to decrease HL-60 cell proliferation and to cause the cells to acquire an ability to phagocytose opsonized yeast and to reduce nitroblue tetrazolium dye, functions characteristic of mature myeloid cells. In addition, this agent at similar concentrations caused a marked depression of intracellular guanosine nucleotide pools and a reduction in the incorporation of [14C] hypoxanthine into guanylates. These results suggested that the selenazole nucleoside caused an inhibition of inosinate monophosphate dehydrogenase, a key enzyme of guanylate biosynthesis. We therefore measured the activity of this enzyme indirectly by simultaneous-UV-radioactivity HPLC as well as by a direct radiometric method and demonstrated markedly reduced enzyme activities by both assays in drug treated cells. Dose response studies indicated that concentrations of drug which caused greater than 30% inhibition of IMP dehydrogenase activity induced greater than 50% maturation of the cells. These observations with this new nucleoside analogue provide further support for the concept that production of guanosine nucleotides and the activity of IMP dehydrogenase have a role in regulating the terminal maturation of myeloid cells.
D002250:Carbon Radioisotopes; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000378:metabolism; D007168:IMP Dehydrogenase / Q000378:metabolism; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000503:physiopathology*; D016566:Organoselenium Compounds; D010084:Oxidation-Reduction; D010587:Phagocytosis / Q000187:drug effects; D012254:Ribavirin / Q000031:analogs & derivatives; D012263:Ribonucleosides / Q000633:toxicity*; D012643:Selenium / Q000633:toxicity*
D002250:Carbon Radioisotopes; D007042:Hypoxanthines; D016566:Organoselenium Compounds; D012263:Ribonucleosides; D019271:Hypoxanthine; D012254:Ribavirin; D007168:IMP Dehydrogenase; D012643:Selenium; C039064:selenazofurin